Background Internal tandem duplication (ITD) of the fms-related tyrosine kinase 3 (FLT3) gene is associated with a poor prognosis in acute myeloid leukemia (AML) patients with a normal karyotype. The current standard polymerase chain reaction (PCR) assay for FLT3/ITD detection is not sufficiently sensitive to monitor minimal residual disease (MRD). Clone-specific assays may have sufficient sensitivity but are not practical to implement, since each clone-specific primer/probe requires clinical validation. Objective To develop an assay for clinical molecular diagnostics laboratories to monitor MRD in FLT3/ITD AMLs. Methods We designed a simple novel assay, tandem duplication PCR (TD-PCR), and tested its sensitivity, specificity, and clinical utility in FLT3/ITD AML patients.
Introduction
Internal tandem duplication (ITD) mutations in the juxtamembrane domain of the fms-related tyrosine kinase 3 (FLT3) gene occur in 20-30 % of patients with acute myeloid leukemia (AML). In AML patients with a normal karyotype, the presence of FLT3/ITD mutations carries a markedly increased rate of relapse and inferior disease-free survival [1] [2] [3] [4] . FLT3/ITD AML patients therefore commonly undergo allogeneic hematopoietic cell transplantation (HCT) [5, 6] . As with other AML patients, relapse following transplantation occurs frequently [7, 8] . ITD mutations provide a potentially useful molecular marker for monitoring minimal residual disease (MRD). FLT3/ITD AML patients with persistent MRD may benefit from HCT. In addition, early detection of MRD followed by donor lymphocyte infusion and/or FLT3 inhibition in the post-transplantation setting could potentially improve disease-free survival.
ITD mutations of the FLT3 gene typically result from headto-tail insertion of a duplicated portion of the juxtamembrane region [9] . ITD mutations occur almost exclusively within exon 14 at random positions. Longer ITDs may extend to involve intron 14 or even exon 15. The current standard-ofcare polymerase chain reaction (PCR) assay (hereafter referred to as the ''standard assay'') detects ITD mutations with primers that straddle the duplicated portion of the juxtamembrane region, resulting in a lengthened product [10] . The limit of detection (or analytic sensitivity) of this assay is approximately 1-5 % mutant alleles in clinical diagnostic laboratories, limiting its utility for detection of MRD. Individualized, clone-specific primers/probes have been designed to improve sensitivity in a strategy similar to clone-specific immunoglobulin gene rearrangement analysis for monitoring MRD of lymphoid malignancies [11] [12] [13] [14] [15] [16] . These FLT3 assays have not been adopted by clinical laboratories, in part because sequence constraints at the ITD junction may limit sensitivity and because validation of each clone-specific primer/probewhich is required for a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the USA-is not practical in terms of time and expense [17, 18] . In this study, we developed a simple, ultra-sensitive assay-tandem duplication PCR (TD-PCR)-that allows clinical MRD monitoring in FLT3/ITD AMLs by using a standardized set of primer pairs and a universal positive control.
Materials and Methods

Patients
Three groups of samples were studied. The first group consisted of peripheral blood or bone marrow specimens from a cohort of 58 ITD-positive AML patients examined by the standard PCR assay at initial diagnosis or relapse in 2009 and 2010 [10] . Only specimens with greater than 20 % blasts were included. Among these 58 ITD-positive patients, the standard assay yielded one ITD (53 specimens), two ITDs (four specimens) and three ITDs (one specimen). These 64 ITDs defined the applicability of TD-PCR for MRD detection. The second group consisted of patients with serial ITD-positive specimens at presentation, ITD-negative bone marrow specimens in clinical remission, and ITD-positive specimens at relapse submitted to our molecular diagnostics laboratory for monitoring of ITD mutations by the standard assay since 2002. After exclusion of patients who underwent HCT, 11 patients were identified. This group was used to test whether minimal residual ITDs could be detected by TD-PCR and how many genomes were required to demonstrate MRD in bone marrow specimens from FLT3/ITD AML patients who achieved remission after standard chemotherapy but relapsed with the same ITD later. The third group was also selected from our laboratory archives. We identified three patients who did not have ITD mutations detected at diagnosis but had newly emerging ITD mutants detected by the standard assay later in their disease course.
TD-PCR
The principle of TD-PCR has been described previously [19] . Briefly, TD-PCR uses a primer pair facing outward, in contrast to a primer pair flanking the ITD in the standard assay (Fig. 1a) . Amplification occurs only when both primers are spanned by the duplicated sequence. The original TD-PCR assay was designed to confirm a minor ITD mutant that was isolated unexpectedly by our DNA fraction collection tool [19, 20] . These TD-PCR primers were located within intron 14 and were applicable to only a minority of long ITDs for MRD detection. In the current design, the primers overlap almost completely (Fig. 1b) , thus shortening the primer span (Fig. 1c) . TD-PCR was performed using six primer pairs tiled across exon 14 and one pair within intron 14 ( Fig. 1c) [see also Supplementary Table S1 in the Electronic Supplementary Material].
PCR
The standard assay was performed as described previously [10] . The TD-PCR reactions were performed separately for each primer pair; the construction of the assay prohibits multiplexing. TD-PCR was performed in a 10 lL volume containing 1 ng or 50 ng of DNA, 5 pmol of each forward and reverse primer, 1.5 mM of MgCl 2 , 0.2 mM of each deoxyribonucleotide, 0.5 units of AmpliTaq Gold DNA polymerase, and 1 lL of buffer, or in a 25 lL volume containing 250 ng of DNA, 12.5 pmol of each forward and reverse primer, 1.5 mM of MgCl 2 , 0.2 mM of each deoxyribonucleotide, 1.25 units of AmpliTaq Gold DNA polymerase, and 2.5 lL of buffer (Applied Biosystems, Foster City, CA, USA). Samples were subjected to 40 cycles of denaturation (at 95°C for 30 s), annealing (at 57°C for 30 s), and extension (at 72°C for 60 s). Capillary electrophoresis was performed and analyzed as described previously [21] .
Confirmation of Analytic Specificity of ITDs
Detected by TD-PCR Long ITDs detected by TD-PCR were confirmed by two methods. First, the sizes of TD-PCR amplicons from adjacent but independently analyzed primer pairs were compared. ITDs with longer duplication segments are expected to be amplifiable by two or more adjacent primer pairs. Amplification by two or more adjacent primer pairs with amplicons of the appropriate sizes indicates duplication-specific amplification from an ITD mutant and is not observed in negative controls ( Supplementary Fig. S1 ). Second, the size of the TD-PCR amplicon was compared with the size detected by the standard assay (Supplementary Fig. S2 ). For those short ITDs amplifiable by only one primer pair or for ITDs with a low level of allelic burden, duplication-specific amplification was confirmed by Sanger sequencing of TD-PCR amplicons.
Sanger Sequencing
TD-PCR products were reamplified using overlapping internal primers tagged with M13F and M13R sequences: TD3F3seq3M13F (5 0 -tgtaaaacgacggccagtGTaatgggTgtttc caagag-3 0 ) and TD3R3Seq3M13R (5 0 -caggaaacagctatg accACgaaTctcccatttgagatc-3 0 ) for TD3 TD-PCR products, or primers TD7F3Seq2M13F (5 0 -tgtaaaacgacggccagttcct cTgataatgagtacttctac-3 0 ) and TD7R3Seq2M13R (5 0 -caggaaacagctatgaccTggagccggtcacctgtacca-3 0 ) for TD7 TD-PCR products. [The capitalized nucleotides in the primer sequences listed above are nucleotides altered to introduce mismatches, and the M13F and M13R sequences are underlined.] PCR products were purified using USB ExoSapit (GE Healthcare, Uppsala, Sweden), cycle sequenced using a BigDye Terminator version 3.1 cycle sequencing kit, according to the manufacturer's protocol, and resolved on an ABI 3500xL sequencer (Applied Biosystems), as described previously [22] . Sequences were analyzed using Sequencher software (Gene Codes Corp., Inc., Ann Arbor, MI, USA).
Results
TD-PCR has Single-Molecule Analytic Sensitivity
We selected an acute myelomonocytic leukemia specimen with a single dominant heterozygous ITD mutant migrating at 456 bases by the standard assay. This marrow was almost entirely packed with blasts and immature myeloid cells. Sanger sequencing of amplicons from both standard PCR and TD-PCR confirmed an ITD of 129 bases (c.1715_1837 ? 6dup) encompassing the sequences of primer pairs TD3, 4, 5, 6, 7, and 9. TD-PCR was conducted in replicates with 50 ng of DNA (equivalent to approximately 8000 cells, assuming each cell contains 6-7 pg of DNA) or 250 ng of DNA (equivalent to approximately 40,000 cells) in each reaction. The expected amplicons were detected in 1 of 1 reaction at dilutions of 10 -3 , 5 9 10 -4 , and 10 -4 , and in 2 to 4 of 4 replicates at a dilution of 5 9 10 -5 of 250 ng of DNA (equivalent to two mutant cells per reaction) (Fig. 2) . Primer pairs TD3, 5, 7, and 9 detected the ITD in 1 of 4 replicates at 10 -5 dilution of 250 ng of DNA (equivalent to 0.4 mutant cells per reaction) (Fig. 2) and in 4-6 of 20 replicates at 5 9 10 TD7 (23) TD6 (26) TD5 (25) TD4 (21) TD3 (21) TD1 ( lower sensitivity, as amplicons were not detected in any of the four replicates at 10 -5 dilution of 250 ng of DNA.
TD-PCR is Applicable for MRD Detection in 75 % of ITDs
We examined 64 ITDs from 58 newly diagnosed or relapsed FLT3/ITD AML patients, using 50 ng of DNA for each of seven primers pairs. Forty-eight ITDs (75 %) with sizes of duplication segments ranging from 36 to more than 170 bases and all larger ITDs (C42 bases) were amplifiable by one or more primer pairs. Amplification of the corresponding ITDs detected by the standard assay was supported by a consistent linear correlation between the estimated TD-PCR amplicon size calculated from the amplicon size determined by the standard assay and the observed TD-PCR amplicon size ( Supplementary Fig. S2 and Supplementary Fig. S3 ). Fig. S4 ).
TD-PCR Detects MRD in Remission
To identify informative pairs, 1 ng of DNA from specimens at presentation was screened by seven TD-PCR primer pairs in 11 patients who relapsed after standard chemotherapy. Seven patients with one or more informative primer pairs were examined in remission. Twelve available marrows that were reportedly ITD negative by the standard assay from these seven patients were tested by TD3 or TD7 primer pairs 1-14 months before relapse with the same ITD ( Table 1 ). The TD-PCR assay was conducted with a sequential increase of DNA input for negative specimens until all 12 marrows had MRD detected. Eight samples required 100 ng of DNA to detect a signal, three samples required 600 ng, and one sample required 1.1 lg (Fig. 3) . These results suggest that a minimum of 1 lg of DNA (equivalent to 160,000 cells) is needed to detect MRD. (MDS/MPD) specimen, were studied to evaluate if the newly evolving ITD mutants were present in the initial diagnostic specimens [Supplementary Table S2 ]. All three patients who were classed as ITD negative by the standard assay but positive by TD-PCR in the initial specimens relapsed/progressed with the TD-PCR FLT3/ ITD as a major clone.
TD-PCR Detects
FLT3/ITD Mutations Occur in Healthy Individuals
Bone marrows from 24 healthy transplant donors were tested by TD-PCR with TD3 and TD7 primers (2-15.5 lg from each individual or 105.5 lg across all individuals, equivalent to approximately 14 million cells, in aggregate, cells. Duplication-specific amplification was also confirmed by another primer pair, TD9 (e, f). TD-PCR products at presentation (c, e) were diluted 100-fold before electrophoresis. Sizes in bases are shown in parentheses. *Off-scale peaks, RFU relative fluorescence units examined for each primer pair). One ITD was detected by TD3 and one by TD7 from two individuals (Fig. 4) . These required 2.4 million cells (15.5 lg of DNA) and 1.5 million cells (9.5 lg of DNA) per individual, respectively. Interestingly, the duplications-227 bases (c.1705-14_1838-11dup) and 335 bases (c.1598-3_1837 ? 6dup)-are out of frame (to our knowledge, not reported before) and longer than the usual AML-associated ones.
Discussion
We have developed an ultra-sensitive TD-PCR assay, which is amenable to clinical laboratory monitoring of MRD in FLT3/ITD AML patients. This addresses an unmet need, since there is no practicable assay currently available for MRD of FLT3/ITD in clinical molecular diagnostics laboratories. The limit of detection is at least 1 in 100,000 and is limited by the total input of DNA rather than the dilution factor, since the wild-type allele is not competitive for amplification. The analytic specificity was demonstrated by duplication-specific amplification, defined as the presence of amplification by two or more adjacent primer pairs with amplicons of the appropriate size (Supplementary Fig. S1 ). It was also confirmed by Sanger sequencing of the TD-PCR amplicons. With the improved design in this study, TD-PCR is applicable for MRD detection in approximately 75 % of ITD mutants. A minimum of 1 lg of DNA is recommended for MRD detection in remission bone marrow specimens. One ITD mutation was detected in an aggregate of 105.5 lg of DNA from normal donors, suggesting approximate 99 % clinical specificity if 1 lg of DNA is used for MRD detection. However, these ''false-positive'' amplicons from normal individuals have unique characteristics, which distinguish them from ''true'' ITDs: they are long in comparison with AML-associated ones and may not be in frame. They occur at very low levels and may not be detectable in subsequent samples, so they are unlikely to be confused with true ITD mutations; however, we do not have follow-up specimens from these normal donors to confirm this.
This assay has also been applied to a cohort of FLT3/ ITD AML patients after allogeneic HCT [23] . In that study, TD-PCR was applicable for MRD detection in 28 (76 %) of 37 patients. TD-PCR predicted relapse with remarkable accuracy using the day-60 post-transplantation marrows as analytes. Of note, the day-60 post-transplantation marrows were all negative by the standard assay. Six (86 %) of seven patients with MRD by TD-PCR have relapsed, compared with only 2 (10 %) of 21 patients who were negative for MRD. Of these two ''false-negative'' patients, one relapsed with no ITD detected and the other relapsed with the same ITD 28 months post-transplantation. MRD was detected by TD-PCR in a marrow sample collected 12 months post-transplantation from the second patient. Seven of 27 specimens collected within 2 months prior to transplantation showed no MRD by TD-PCR. All seven patients were negative by TD-PCR at day 60 post-transplantation and did not relapse with follow-up of 12-102 months. TD-PCR may be useful to identify patients who may not need HCT and to identify patients who will benefit from post-transplantation immunotherapy using a donor lymphocyte infusion or maintenance therapy using tyrosine kinase inhibitors.
Clone-specific PCR has been a sensitive assay for detection of FLT3/ITD mutational status and lymphoid malignancies [11] [12] [13] [14] [15] [16] . The analytic sensitivity, however, varied depending on the context of the junctional sequences. The advantage of TD-PCR is the use of common primers rather than customized, clonal-specific primers. Up to 60 % of ITD mutants can be analyzed by TD-PCR using only primer pair 3 or primer pair 7. This has practical implications for testing: US CLIA certification requires a laborious validation process to confirm the analytic and clinical performance characteristics of each custom primer set [17] . We are unaware of a single clinical laboratory offering clone-specific FLT3 PCR in the USA. TD-PCR is designed for MRD detection. The conventional PCR assay is still the standard of care for ITD detection in newly diagnosed AMLs [10] . In this study, we designed the forward and reverse primers by using nearly complimentary sequences to reduce the primer span, and we introduced mismatched nucleotides within the 5 0 end and/or the middle portion of the primers to reduce annealing of primer pairs to each other. We thereby successfully validated the revised TD-PCR assays with broader applicability, while keeping the ultra-high sensitivity. TD-PCR, however, is still only applicable to ITDs longer than approximately 40 bases. On the other hand, very long ITDs appear to be a challenge for next-generation sequencing (NGS) methods to detect, requiring specialized bioinformatics or possibly longer sequencing technology [24] . A recent MRD study reported successful NGS detection of all ITDs tested (\100 bases), except for an 183-base ITD [25] . While a universal solution may ultimately be provided by NGS [26] , a currently feasible and comprehensive MRD assay could be based upon NGS for short ITD detection and TD-PCR for longer ITD detection. In support of this approach, our preliminary NGS data show a limit of detection of 10 -5 for the canonical 30-base ITD of the MV4-11 cell line.
Clinical application of TD-PCR is also limited by the instability of FLT3/ITD status. On average, 17 % (6-33 %) of FLT3/ITD patients relapse without any ITD mutation, but 14 % (7-27 %) of AML patients without a mutation by the standard assay relapse with an ITD mutation-which is a particular drawback for clone-specific primer approaches (Table 2 ) [1, [27] [28] [29] [30] [31] . The observed incidence of newly emerging ITD mutants is likely influenced by the analytic sensitivity of assays used to detect ITD mutations at diagnosis. TD-PCR found low-level ITDs that were undetectable by the standard assay not only in FLT3/ITD AMLs but also in AML patients who were reportedly negative for ITD by the standard assay. We demonstrated that those so-called newly evolving ITD mutants were indeed present at very low levels in the initial diagnostic specimens. This has also been demonstrated by using clone-specific PCR [32] , suggesting a need to identify ITD mutations that are undetectable by conventional PCR assays. While the clone-specific assay can be only retrospectively applied to this group of patients, TD-PCR can be prospectively applied to approximately 60-70 % of patients without knowledge of the ITD sequences, by using, for example, primer pairs 3 and 7.
Multiple ITD mutations may be more common than previously believed. In this study, we demonstrated multiple minor ITD mutants that were undetectable by the standard PCR assay in FLT3/ITD AML patients. The clinical significance of multiple ITD mutations, however, is controversial [1, 33, 34] , partly because the definition of multiple ITD mutations varies depending on the analytic sensitivity of assays. By using TD-PCR and our DNA fraction collection tool, we identified FLT3/ITD AML patients with five or more ITD mutants [20] . The presence of multiple ITD mutations suggests that ITD is a later event rather than an initiating driver mutation for leukemogenesis in a portion of FLT3/ITD AMLs [35, 36] .
Conclusion
TD-PCR is a simple, ultra-sensitive assay for monitoring MRD in a large portion of FLT3/ITD AML patients. In contrast to assays using clone-specific primers/probes, TD-PCR is amenable to clinical validation in molecular diagnostics laboratories by using a standard set of primer pairs and a universal positive control. TD-PCR also detected cases of low-level multi-clonality of ITD mutants. 
